Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05830877
Other study ID # 2023ZL476
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 10, 2023
Est. completion date December 31, 2025

Study information

Verified date June 2024
Source The Third Affiliated hospital of Zhejiang Chinese Medical University
Contact Yingjun Liu, DR.
Phone 15958033054
Email frankly120@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Through the recruition of outpatients who clinically meet the diagnostic criteria and inclusion criteria of PI, the acupuncture group adopts Tiaoshen acupuncture, and the placebo acupuncture group adopts non-insertive acupuncture supported by the Park device, and the Pittsburgh Sleep Quality Index (PSQI) is used as the main index to evaluate the patients through the scale; subjective indicators like Chalder 14-item fatigue scale, Epworth sleepiness rating, self-rating anxiety scale (SAS), self-rating depression scale (SDS) and objective indicators like polysomnography (PSG), heart rate variability (HRV) is regarded as a secondary index, and then evaluate the clinical efficacy of Tiaoshen acupuncture on PI and explore its mechanism.


Recruitment information / eligibility

Status Recruiting
Enrollment 84
Est. completion date December 31, 2025
Est. primary completion date June 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Conforming to the diagnostic criteria of traditional Chinese and Western medicine for chronic insomnia; - Age range: 18-70 years old; - PSQI score>7 points; SAS score > 50 or SDS score > 53; - No communication and cognitive impairment; - No use or withdrawal of psychoactive drugs such as anti-anxiety within one month; ·No major physical diseases; - Those who voluntarily accept the research content and can complete various scale evaluations, polysomnography monitoring and HRV; - Sign an informed consent form prior to the start of the study. Exclusion Criteria: - Those who do not meet the inclusion criteria; - Persons with a history of severe mental illness, severe head injury, and significant disturbance of consciousness; - Those with severe liver and renal insufficiency and bleeding tendencies; - Alcoholism (liquor = 100ml/day), smoking (= 15 cigarettes/day), drug abuse or taking psychotropic drugs; - People with other sleep disorders, such as sleep apnea hypopnea syndrome, paroxysmal sleeping sickness, and REM sleep behavioral disorders; - Pregnant or nursing; - Those with other major diseases and poor control; - Other persons who are unwilling to sign informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
the acupuncture group
The primary choice is to puncture GB20 with a quick puncture, which means "regulate the mind and open the way". ?Scalp acupuncture: Du 20(Baihui), EX-HN 3(Yintang), EX-HNl(Sishencong); ?Select acupoints from six acupoints for mind-regulating, ear points (both sides): heart, lung, and Shenmen; body points (both sides): LI20(Yingxiang), EXTRA 12(Anmian), ST36(Zusanli) as the main hole. ?Sleeping three needles(both sides): HT7(Shenmen), PC6(Neiguan), SP6(Sanyinjiao); ?Opening four gates: LI4(Hegu) , LR3(Taichong) ?Abdominal four needles:ST25(Tianshu), CV12(Zhongwan), CV4(Guanyuan). For body acupuncture, a 0.3 mm×40 mm needle was used to insert directly for 0.5-1.0 cun, and twisting to gain the qi; for auricular points, a 0.25 mm×40 mm needle was used for 2-3 minutes without manipulating the needle. The acupuncture points were retained for 30 min, and the treatment was performed once every other day, three times a week, and the curative effect was evaluated after 4 weeks of treatment.
the placebo acupuncture group
Subjects in the placebo acupuncture group will receive non-insertive acupuncture using the sham needle supported by the Park device. This needle has a retractable shaft and a blunt tip, they could not penetrate the skin. We gently placed the sham needle and Park device on the skin. The sham needle is then no longer manipulated to minimize any physiological effects. The selected acupoints and needle retention time were the same as for the acupuncture group. Since oblique insertion is required for acupuncture points on the head, the fixed acupuncture body of the Park device could not be used. Therefore, blunt needles are used to stimulate the head points to reduce the amount of stimulation produced by acupuncture. At the end of the treatment, the acupuncturist also used a dry cotton swab to press the acupoints so that patients could feel the withdrawal of 'real' needles.

Locations

Country Name City State
China The Third Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
The Third Affiliated hospital of Zhejiang Chinese Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pittsburgh sleep quality index Use the PSQI score table to evaluate according to patient's situation, and analyze the score changes of the subjects' insomnia degree before and after treatment by the analysis of score data. The PSQI consists of 19 self-rated questions and 5 questions rated by sleep partners. The 19 self-assessment questions constitute 7 factors ranging from 0 to 3 points. The cumulative score of each factor component is the total score of the PSQI, and the total score ranges from 0 to 21. The higher the score, the worse the sleep quality. Before treatment
Primary Pittsburgh sleep quality index Use the PSQI score table to evaluate according to patient's situation, and analyze the score changes of the subjects' insomnia degree before and after treatment by the analysis of score data. The PSQI consists of 19 self-rated questions and 5 questions rated by sleep partners. The 19 self-assessment questions constitute 7 factors ranging from 0 to 3 points. The cumulative score of each factor component is the total score of the PSQI, and the total score ranges from 0 to 21. The higher the score, the worse the sleep quality. the 4th week of treatment
Primary Pittsburgh sleep quality index Use the PSQI score table to evaluate according to patient's situation, and analyze the score changes of the subjects' insomnia degree before and after treatment by the analysis of score data.The PSQI consists of 19 self-rated questions and 5 questions rated by sleep partners. The 19 self-assessment questions constitute 7 factors ranging from 0 to 3 points. The cumulative score of each factor component is the total score of the PSQI, and the total score ranges from 0 to 21. The higher the score, the worse the sleep quality. 4 weeks after treatment
Secondary Fatigue Scale-14 Respond to the severity of fatigue from different angles through 14 questions.The Fatigue Scale-14 is composed of 14 items, and the 14 items are divided into two categories. One category reflects physical fatigue, including 1 to 8 items; the other reflects mental fatigue, including 9 to 14 in total 6 items. The highest score for physical fatigue is 8, the highest score for mental fatigue is 6, and the highest total score is 14. The higher the score, the more severe the fatigue. Before treatment
Secondary Fatigue Scale-14 Respond to the severity of fatigue from different angles through 14 questions.The Fatigue Scale-14 is composed of 14 items, and the 14 items are divided into two categories. One category reflects physical fatigue, including 1 to 8 items; the other reflects mental fatigue, including 9 to 14 in total 6 items. The highest score for physical fatigue is 8, the highest score for mental fatigue is 6, and the highest total score is 14. The higher the score, the more severe the fatigue. the 4th week of treatment
Secondary Fatigue Scale-14 Respond to the severity of fatigue from different angles through 14 questions.The Fatigue Scale-14 is composed of 14 items, and the 14 items are divided into two categories. One category reflects physical fatigue, including 1 to 8 items; the other reflects mental fatigue, including 9 to 14 in total 6 items. The highest score for physical fatigue is 8, the highest score for mental fatigue is 6, and the highest total score is 14. The higher the score, the more severe the fatigue. 4 weeks after treatment
Secondary Epworth Sleepiness Scale The epworth sleepiness scale is applied to assess excessive daytime sleepiness. The clinical significance of this table is: sleepiness can be semi-objectively assessed by the epworth sleepiness scale. Any sleep disorder caused by sleep deprivation may lead to change of this scale. This scale has 24 points. A score greater than 6 indicates drowsiness, a score greater than 11 indicates excessive sleepiness, and a score greater than 16 indicates dangerous drowsiness. Before treatment
Secondary Epworth Sleepiness Scale The epworth sleepiness scale is applied to assess excessive daytime sleepiness. The clinical significance of this table is: sleepiness can be semi-objectively assessed by the epworth sleepiness scale. Any sleep disorder caused by sleep deprivation may lead to change of this scale. This scale has 24 points. A score greater than 6 indicates drowsiness, a score greater than 11 indicates excessive sleepiness, and a score greater than 16 indicates dangerous drowsiness. he 4th week of treatment
Secondary Epworth Sleepiness Scale The epworth sleepiness scale is applied to assess excessive daytime sleepiness. The clinical significance of this table is: sleepiness can be semi-objectively assessed by the epworth sleepiness scale. Any sleep disorder caused by sleep deprivation may lead to change of this scale. This scale has 24 points. A score greater than 6 indicates drowsiness, a score greater than 11 indicates excessive sleepiness, and a score greater than 16 indicates dangerous drowsiness. 4 weeks after treatment
Secondary Self-Rating Anxiety Scale SAS is called anxiety self-rating scale, which is a standard for anxiety assessment and a psychological scale used to measure the degree of anxiety state and its changes during treatment. The SAS scale has 100 points in total, and the cut-off value is 50 points, of which 50-59 points are mild anxiety, 60-69 points are moderate anxiety, and more than 70 points are severe anxiety. Before treatment
Secondary Self-Rating Anxiety Scale SAS is called anxiety self-rating scale, which is a standard for anxiety assessment and a psychological scale used to measure the degree of anxiety state and its changes during treatment. The SAS scale has 100 points in total, and the cut-off value is 50 points, of which 50-59 points are mild anxiety, 60-69 points are moderate anxiety, and more than 70 points are severe anxiety. 4th week of treatment
Secondary Self-Rating Anxiety Scale SAS is called anxiety self-rating scale, which is a standard for anxiety assessment and a psychological scale used to measure the degree of anxiety state and its changes during treatment. The SAS scale has 100 points in total, and the cut-off value is 50 points, of which 50-59 points are mild anxiety, 60-69 points are moderate anxiety, and more than 70 points are severe anxiety. 4 weeks after treatment
Secondary Self-rating depression scale The depression self-rating scale is a standard for depression assessment, which can quite intuitively reflect the subjective feelings of depressed patients during treatment. It is mainly applicable to adults with depressive symptoms, including outpatients and inpatients. The SDS scale has 100 points in total, and the cut-off value is 53 points, of which 53-62 points are mild anxiety, 63-72 points are moderate anxiety, and more than 73 points are severe anxiety. Before treatment
Secondary Self-rating depression scale The depression self-rating scale is a standard for depression assessment, which can quite intuitively reflect the subjective feelings of depressed patients during treatment. It is mainly applicable to adults with depressive symptoms, including outpatients and inpatients. The SDS scale has 100 points in total, and the cut-off value is 53 points, of which 53-62 points are mild anxiety, 63-72 points are moderate anxiety, and more than 73 points are severe anxiety. the 4th week of treatment
Secondary Self-rating depression scale The depression self-rating scale is a standard for depression assessment, which can quite intuitively reflect the subjective feelings of depressed patients during treatment. It is mainly applicable to adults with depressive symptoms, including outpatients and inpatients. The SDS scale has 100 points in total, and the cut-off value is 53 points, of which 53-62 points are mild anxiety, 63-72 points are moderate anxiety, and more than 73 points are severe anxiety. 4 weeks after treatment
Secondary Polysomnography Polysomnography refers to the continuous and synchronous acquisition, recording and analysis of EEG, electrooculogram, electromyogram, oronasal airflow, respiratory effort, and saturation of oxygen levels, body position and other physiological and pathological parameters during sleep by sleep technicians all night through computer software in the sleep laboratory. This technology for the diagnosis of sleep disorders is the gold standard for the diagnosis and treatment of sleep disorders. the 4th week of treatment
Secondary Heart rate variability Heart rate variability (HRV) refers to the fluctuations in the interval between successive heartbeats. It is commonly used to evaluate the regulatory role of the autonomic nervous system on cardiac activity. It is an important noninvasive indicator for evaluating autonomic nervous activity, and is also one of the important indicators for evaluating autonomic nervous changes during sleep. the 4th week of treatment
See also
  Status Clinical Trial Phase
Terminated NCT03461666 - Comparison of Efficacy of Behavioral Approaches for Treatment of Insomnia N/A
Recruiting NCT02243501 - Better Nights, Better Days for Typically Developing Children N/A
Completed NCT01636791 - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care Phase 3
Completed NCT00770510 - A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126) Phase 2/Phase 3
Completed NCT00520832 - A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys Phase 2
Recruiting NCT00415714 - Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia N/A
Terminated NCT00420810 - Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED) Phase 3
Completed NCT00178048 - Paroxetine in the Treatment of Chronic Primary Insomnia Phase 4
Completed NCT00816673 - Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs Phase 2
Completed NCT01957111 - Metabolomics of Insomnia-Related Hyperarousal N/A
Completed NCT01960452 - A High Density EEG Comparison of Sleep Patterns in Insomnia N/A
Completed NCT01181232 - A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients Phase 4
Completed NCT00784875 - An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia Phase 2
Completed NCT00551148 - A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia Phase 2
Completed NCT00397189 - Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients Phase 3
Completed NCT00352144 - 6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia Phase 3
Completed NCT02290405 - Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
Completed NCT03314441 - Effects of Regular Practice of Yoga on Subjective and Objective Sleep Quality in Primary Insomnia N/A
Completed NCT00792298 - Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006) Phase 2
Completed NCT01021852 - Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011) Phase 2